Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$5.32 USD

5.32
1,352,180

+0.10 (1.92%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

by Zacks Equity Research

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of 157.69% and 119.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

by Zacks Equity Research

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 80% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

by Zacks Equity Research

Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

by Zacks Equity Research

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks to Consider for Your Portfolio in 2024

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

What Makes Editas (EDIT) a New Buy Stock

by Zacks Equity Research

Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

by Zacks Equity Research

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

by Zacks Equity Research

Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

by Zacks Equity Research

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News

by Zacks Equity Research

bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

by Zacks Equity Research

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data

by Zacks Equity Research

Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.

Ekta Bagri headshot

3 Biotechs With Promising Gene Therapies in the Spotlight

by Ekta Bagri

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

Kevin Cook headshot

Bull of the Day: CRISPR Therapeutics (CRSP)

by Kevin Cook

FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why

by Zacks Equity Research

CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

by Zacks Equity Research

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 14.06% and 5.50%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

by Zacks Equity Research

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.

Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.